CT1-DAP001 for Parkinson's Disease
This study is testing a new treatment called CT1-DAP001 for people with Parkinson's disease. CT1-DAP001 is made from human induced pluripotent stem cells (special cells that can turn into different types of cells) and is designed to replace brain cells that are lost in Parkinson's. Researchers want to see if CT1-DAP001 is safe and how well it helps with Parkinson's symptoms. You might be able to join if you are between 40 and 75 years old, have had Parkinson's for at least 5 years, and your current medications aren't working well enough. The study is looking for 7 participants and its current status is unclear.
- Study design
- This is a single-center, open-label study, meaning everyone knows what treatment is being given. It is planned for 7 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be checked for 24 months after the treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
At a glance
Conditions
NCT06482268
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Diego
La Jolla, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Joseph Ciacci, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence And Severity Of Adverse Events24 months
For adverse events reported, the severity will be assessed, and the incidence in the treatment period will be determined.
- ACCEPTABILITY24 months
Assessed by presence or absence of graft expansion (\> 3 cm3) in the brain at 24 months after transplantation